19569964

Source:http://linkedlifedata.com/resource/pubmed/id/19569964

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008059, umls-concept:C0032339, umls-concept:C0036043, umls-concept:C0206255, umls-concept:C0443252, umls-concept:C1510693, umls-concept:C1539358
pubmed:issue	3
pubmed:dateCreated	2009-7-9
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00197041, http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00323622
pubmed:abstractText	We previously reported that the RTS,S/AS02A vaccine had an acceptable safety profile, was immunogenic, and demonstrated efficacy against Plasmodium falciparum malaria disease for 21 months.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/19569964-19569963, http://linkedlifedata.com/resource/pubmed/commentcorrection/19569964-19569965
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0413675
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Protozoan, http://linkedlifedata.com/resource/pubmed/chemical/Malaria Vaccines
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	0022-1899
pubmed:author	pubmed-author:AidePedroP, pubmed-author:AlonsoPedro LPL, pubmed-author:AponteJohn JJJ, pubmed-author:BallouW RipleyWR, pubmed-author:BassatQuiqueQ, pubmed-author:CohenJoeJ, pubmed-author:DemoitiéMarie-AngeMA, pubmed-author:DuboisMarie-ClaudeMC, pubmed-author:GuinovartCaterinaC, pubmed-author:LafuenteSarahS, pubmed-author:LeachAmandaA, pubmed-author:LievensMarcM, pubmed-author:MaceteEusébioE, pubmed-author:MandomandoInácioI, pubmed-author:MenéndezClaraC, pubmed-author:MilmanJessicaJ, pubmed-author:RenomMontseM, pubmed-author:SacarlalJahitJ, pubmed-author:SigaúqueBetuelB, pubmed-author:SillmanMarlaM, pubmed-author:ThonnardJoelleJ, pubmed-author:VekemansJohanJ
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	200
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	329-36
pubmed:dateRevised	2009-11-12
pubmed:meshHeading	pubmed-meshheading:19569964-Antibodies, Protozoan, pubmed-meshheading:19569964-Child, Preschool, pubmed-meshheading:19569964-Cross-Sectional Studies, pubmed-meshheading:19569964-Follow-Up Studies, pubmed-meshheading:19569964-Humans, pubmed-meshheading:19569964-Infant, pubmed-meshheading:19569964-Malaria, Falciparum, pubmed-meshheading:19569964-Malaria Vaccines, pubmed-meshheading:19569964-Mozambique, pubmed-meshheading:19569964-Parasitemia, pubmed-meshheading:19569964-Time Factors
pubmed:year	2009
pubmed:articleTitle	Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.
pubmed:affiliation	Centro de Investigação em Saúde de Manhiça (CISM) Manhiça, Mozambique. jahit.sacarlal@manhica.net
pubmed:publicationType	Journal Article, Comment, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II